Tag Archives: American Association for Cancer Research

December, 2017

4 December
Bayer and Loxo Oncology Report Positive Updated Larotrectinib Pediatric Phase 1 Trial Data

WHIPPANY, N.J., Dec. 4, 2017 /PRNewswire/ — Bayer and Loxo Oncology, Inc., (NASDAQ: LOXO), today announced updated clinical data from the larotrectinib (LOXO-101) pediatric Phase I SCOUT trial (NCT02637687). These data are being presented today at the American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer Research in …
Share

16 August
Liquid Biopsies Find Distinct Genomic Profiles in Most Patients with Carcinoma of Unknown Primary

PHILADELPHIA — Next-generation sequencing of circulating tumor DNA (ctDNA) identified distinct genomic profiles with potentially targetable alterations in 99.7 percent of patients with carcinoma of unknown primary (CUP) who have detectable alterations, according to results published in Cancer Research, a journal of the American Association for Cancer Research. “Our research is the first …
Share

21 July
COX-2 Inhibitors May Reverse IDO1-Mediated Immunosuppression in Some Cancers

Bottom Line: In preclinical studies, tumors that consitutively expressed the protein indoleamine 2,3-dioxygenase (IDO1) responded to the cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex) and had improved infiltration of certain subsets of T cells, making them more likely to respond to anti-PD1 therapies. Journal in Which the Study was Published: Cancer Immunology Research, …
Share

14 April
Glioblastoma Patients May Benefit from a Vaccine-Chemotherapy Combination

Bottom Line: A vaccine targeting cytomegalovirus (CMV) antigen pp65, combined with high-dose chemotherapy (temozolomide), improved both progression-free survival and overall survival for a small group of glioblastoma (GBM) patients. Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research. Author: Lead …
Share
3 April
Bristol-Myers Squibb’s Immunotherapy Combination Extends Survival in Patients with Melanoma

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the first overall survival (OS) data from the Phase 3 CheckMate -067 clinical trial. With a minimum follow-up of 28 months, the median OS had not yet been reached in either of the two Opdivo treatment groups and was 20 months for …
Share

17 November
FDA Research to Help Speed Development of Zika Virus Vaccines and Therapeutics

A new mouse model developed by scientists at the U.S. Food and Drug Administration may help in exploring the potential activity of Zika virus vaccines and therapeutics. Published today in PLoS Pathogens, is the description of a neonatal mouse model that provides a platform for potentially improving and expediting studies …
Share

12 August
Venetoclax Safe, Shows Promise in Patients with Acute Myelogenous Leukemia

Bottom Line: Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), with complete remissions in some, according to phase II clinical trial data. Journal in Which the Study …
Share

22 April
Juno’s Investigational CAR T Cell Product Candidates Show Promise in Patients with B-Cell and Mesothelioma Cancers

SEATTLE–(BUSINESS WIRE)–Apr. 20, 2016– Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced, in partnership with its collaborators, early clinical data from two oral presentations for two product candidates at the American Association for Cancer Research …
Share

10 December
Study Finds Breast-Conserving Therapy Yielded Better Outcomes than Mastectomy for Patients with Early-Stage Breast Cancer

SAN ANTONIO — Among patients with early-stage breast cancer, those who received breast- conserving surgery plus radiation therapy had improved overall survival after 10 years compared with those who received mastectomy without radiation therapy, according to data presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8–12. “Comparison of …
Share